Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 1835 results for carers

  1. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]

    Awaiting development Reference number: GID-TA11826 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]

    Awaiting development Reference number: GID-TA11830 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]

    Awaiting development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development